5:41 PM
 | 
Nov 08, 2012
 |  BC Extra  |  Clinical News

BioCryst plummets on peramivir setback

Shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) fell $0.99 (40%) to $1.46 on Thursday after the company discontinued for futility the Phase III BCX1812-301 trial of peramivir to treat patients hospitalized for serious influenza infection. The discontinuation was based on a pre-planned interim analysis of 119 patients not treated with neuraminidase inhibitors as standard of care (SOC). According to BioCryst, the interim analysis showed only a "small difference" on the primary endpoint of time to clinical resolution...

Read the full 372 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >